Skip to search formSkip to main contentSkip to account menu

selexipag

Known as: 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Introduction: Selexipag, an oral selective prostacyclin receptor agonist, delays disease progression versus placebo in pulmonary… 
2017
2017
1Division of Pediatric Cardiology, Department of Pediatrics, Medical University Graz, Austria 2Department of Neonatology, Charit… 
2017
2017
markdownabstractCongenital diaphragmatic hernia (CDH) is a severe anomaly characterized by a diaphragmatic defect, lung… 
2016
2016
The invention discloses a synthetic method of selexipag. According to the method, 4-[(t-butyloxycarboryl)(isopropyl) amino]-1… 
2016
2016
The aim of this single-center, open-label study was to assess the absolute bioavailability of an oral (tablet) versus intravenous… 
2016
2016
La presente invention concerne des formes a l'etat solide de selexipag, en particulier des formes IV et V de selexipag, et des… 
2016
2016
Lesinurad (Zurampic) for gout-related hyperuricemia; selexipag (Uptravi) for pulmonary arterial hypertension; sugammadex (Bridion… 
2015
2015
1 Integrin Adhesions and the Myogenic Response of Rat Cerebral Arteries Colinas O, Moreno-Dominguez A, Zhu H-L, Zhong XZ, Walsh…